Rebecca Shatsky
Associate Professor of Medicine
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Rebecca Shatsky is an Associate Professor of Medicine at the University of California San Diego Medical Center. Her research focuses on breast cancer management, including systemic therapies, endocrine treatments, and targeted therapies for various stages of the disease. Recent contributions include studies on datopotamab-deruxtecan in early-stage breast cancer and cancer pain characteristics in emergency settings.
Articles (10)
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Objectives: To identify patient characteristics and treatment factors of patients presenting to the emergency department (ED) with cancer-related pain that may affect patient outcomes. Methods: We conducted a retrospective cohort study to evaluate adult patients with active cancer, who presented to the ED with a chief complaint of pain between June first, 2012 and January first, 2016. We utilized multivariable logistic regression to evaluate the association of several exposure variables, including disease and demographic characteristics, primary pain site, and treatment methods, on ED disposition and revisit rate. Results: We included 483 patients with active cancer with a chief complaint of pain. Patients with severe pain on arrival tended to be younger than those who did not present with severe pain (median: 58 vs 62 respectively, OR 8.0 p < 0.01). Patients with high ECOG scores (3-4) with severe pain on arrival (≥7 out of 10) had less improvement in their pain than the rest of our cohort (OR 8.4, p < 0.01). Also, those with musculoskeletal pain had significantly less improvement in reported pain than all other pain types (delta pain −2.1 vs −3.4, OR 2.3, p = 0.025) Long delays in initial analgesic administration were associated with increased rates of subsequent admission (OR 3.4) [p = 0.014]. Although opioid analgesics led to greater decreases in pain than non-opioid analgesics, patients treated with opioids were more likely to be admitted (43% vs 34.5% AOR 1.51, p = 0.048). Conclusion: Our study showed that delays in analgesic administration, poor functional status, and the presence of musculoskeletal (MSK) pain significantly influenced outcomes for this patient cohort. These findings suggest the development of specific protocols and tools to address cancer-related pain in the ED may be necessary.
Year:
2022
Year:
2022
Collaborators (4)
Nusrat Jahan
Assistant Professor
The University of Alabama
Christopher J. Coyne
University of California, San Diego
Gillian Hirst
Assistant Professor
University of California, San Francisco
Lesley Fallowfield
Director, Professor of Psycho-oncology
University of Sussex
Make your next move.
Prepare your application
Review drafts before you send them.